This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Amarantus Biosciences And RBCC Announce NuroPro Parkinson's Diagnostic As Target For Joint Venture

Rainbow Coral Corp. (OTCBB: RBCC) biotech subsidiary Rainbow BioSciences and Amarantus Biosciences (OTCBB: AMBS) have moved into the final stages of the terms for a deal. The pending joint venture agreement will see the two entities working together to move the Amarantus NuroPro Parkinson’s diagnostic platform towards commercialization.

“This is a cutting edge approach to diagnosing a debilitating disease that has afflicted millions of people worldwide,” said RBCC CEO Patrick Brown. “The marketplace is crying out for new breakthroughs in the diagnosis of neurological diseases, and we believe NuroPro has the potential to diagnose Parkinson’s disease early allowing physicians to initiate treatment regimens earlier, as well as conduct research of clinical-stage disease-modifying treatments on earlier-stage patients.”

The deal is being structured to enable completion of the final stages of the NuroPro program, resulting in a commercially viable product to be introduced to the market place. NuroPro is being developed for the diagnosis of Parkinson’s disease. The NuroPro test works by identifying differentiated levels proteins and peptides in the blood of patients who have Parkinson’s disease, versus those who do not. NuroPro has completed a Phase 1 human clinical trial. The companies expect to initiate Phase 2 clinical studies in 2013. It is expected that upon completing Phase 2, NuroPro would begin generating revenue through sales under the Clinical Laboratory Improvement Amendment (CLIA) certification.

“Amarantus’ focus on Parkinson’s disease has allowed it to gain considerable traction with partners who understand the potential value of the technologies we have in-house,” said Gerald E. Commissiong, President & CEO of Amarantus. “This transaction will allow Amarantus to gain upside from the licensing of the NuroPro asset, while defraying the costs of the project in order to focus our internal resources on the MANF Program for Parkinson’s disease and Traumatic Brain Injury. As NuroPro advances towards commercialization, we expect it could become a key differentiating component of our clinical development program of MANF for Parkinson’s disease.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,081.46 +137.65 0.81%
S&P 500 1,977.99 +10.42 0.53%
NASDAQ 4,438.9430 +23.4530 0.53%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs